Slingshot members are tracking this event:

FibroGen Publishes Roxadustat Phase 2 Data on Patients with Chronic Kidney Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data FibroGen announced the Phase 2 Anemia data that demonstrated Roxadustat's ability to maintain hemoglobin levels in patients with chronic kidney disease. Roxadustat doses of 1.5 mg/kg or greater achieved greater Hb response than epoetin alfa, with a pooled response at 6 weeks of 79% compared to 33% in those receiving epoetin alfa.  "Examining the primary endpoint, 51% of subjects receiving roxadustat were able to achieve a Hb level > 11.0 g/dL over the last four weeks of the 19-week treatment period compared with 36% of those receiving epoetin alfa. "  
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Data, Chronic Kidney Disease, Roxadustat